AI assistant
Wockhardt Ltd — Capital/Financing Update 2022
May 15, 2022
59231_rns_2022-05-15_134026f5-4338-4ec6-8b95-5f0fef2811ef.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [178 x 49] intentionally omitted <==
Ref. No.: WOCK/SEC/SE/2022-23/007
15[th] May, 2022
BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers, Dalal Street Bandra Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA
Sub: Statement on Deviation or Variation of funds raised through Rights Issue for the quarter ended 31[st] March, 2022
Dear Sir/Madam,
Pursuant to Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019, we hereby confirm that there has been no deviation in the utilisation of Issue proceeds from the objects as stated in the Letter of Offer for Rights Issue dated 4[th] March 2022.
The ‘Statement of deviation’, confirming Nil deviation, duly reviewed by the Audit Committee is attached herewith as ‘ Annexure A ’.
Kindly take the above information on record.
Thanking you,
for Wockhardt Limited
==> picture [121 x 55] intentionally omitted <==
Debashis Dey Company Secretary
Encls: A/a.
==> picture [112 x 49] intentionally omitted <==
==> picture [513 x 32] intentionally omitted <==
Annexure A
==> picture [178 x 49] intentionally omitted <==
Statement of Deviation / Variation in utilisation of funds raised
| Name of the Company | Wockhardt Limited |
|---|---|
| Mode of Fund Raising | Rights Issue |
| Date of Raising Funds | 28-03-2021 |
| Amount Raised (in Rs. Crores) | 748 |
| Report filed for Quarter ended | 31-03-2022 |
| Monitoring Agency | Applicable |
| Monitoring Agency Name, if applicable | Care Ratings Limited |
| Is there a Deviation / Variation in use of funds raised | No |
| If yes, whether the same is pursuant to change in | NA |
| terms of a contract or objects, which was approved by | |
| the shareholders | |
| If Yes, Date of shareholder Approval | NA |
| Explanation for the Deviation / Variation | NA |
| Comments of the Audit Committee after review | No Deviation |
| Comments of the auditors, if any | NA |
Objects for which funds have been raised and where there has been a deviation, in the following table
| Original Object | ModifiedObject, if | OriginalAllocation | Modifiedallocatio | FuUt | ndsilised | Amount ofDeviation/Variatio | Remarks if any |
|---|---|---|---|---|---|---|---|
| any | (Rs. incrore) | n, if any | n for the quarteraccording toapplicable object | ||||
| Repayment, in full or part, ofcertain subordinated debtand certain outstandingborrowings (including | No | 590 | Nil | 500 | Nil | NA | |
| interest) availed by theCompany | |||||||
| General corporatepurposes | No | 152 | Nil | 55 | .40 | Nil | NA |
| Total Net Proceeds* | 742 | 55 | 5.40 |
- Excluding estimated ‘Issue related expenses’.
Deviation or variation could mean:
(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc
==> picture [121 x 56] intentionally omitted <==
Name of the Signatory : Debashis Dey
Designation : Company Secretary & Compliance Officer
==> picture [112 x 49] intentionally omitted <==
==> picture [513 x 32] intentionally omitted <==